跳至主要内容
临床试验/IRCT20220218054057N1
IRCT20220218054057N1招募中3 期

Omalizumab Efficacy in Chronic Rhinosinusitis Patients with Recurrent and Refractory Nasal Polyps, Randomized Clinical trial

Shiraz University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 60 years(—)
性别
All

入选标准

  • Investigation in Namazi Hospital Immunology -Allergy Clinic Complete the informed consent form Patients aged 18-75 years Usage of intranasal corticosteroid Nasal Polyp score 2 or more Total Congestion Nasal score 2 or higher SNOT22 score 20 or higher on arrival

排除标准

  • The patients with other sinunasal or pulmonary disorders (except asthma) History of past or current malignancy History of a cardiac condition, hepatitis or liver cirrhosis History of recent or current infection requiring hospitalization History of recent use of immunosuppressant and biologics History of recent nasal surgery (<6 months). known allergy to omalizumab

研究者

相似试验